JP2008512394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512394A5 JP2008512394A5 JP2007530543A JP2007530543A JP2008512394A5 JP 2008512394 A5 JP2008512394 A5 JP 2008512394A5 JP 2007530543 A JP2007530543 A JP 2007530543A JP 2007530543 A JP2007530543 A JP 2007530543A JP 2008512394 A5 JP2008512394 A5 JP 2008512394A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- epha4
- antagonist
- receptor
- rnai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000021727 EphA4 Receptor Human genes 0.000 claims 16
- 108010055179 EphA4 Receptor Proteins 0.000 claims 16
- 239000000126 substance Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 13
- 108091030071 RNAI Proteins 0.000 claims 8
- 230000009368 gene silencing by RNA Effects 0.000 claims 8
- 206010018341 Gliosis Diseases 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 102000050554 Eph Family Receptors Human genes 0.000 claims 5
- 108091008815 Eph receptors Proteins 0.000 claims 5
- 229940122293 Ephrin antagonist Drugs 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000007387 gliosis Effects 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 230000003376 axonal effect Effects 0.000 claims 3
- 206010061431 Glial scar Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 230000009036 growth inhibition Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004905148A AU2004905148A0 (en) | 2004-09-08 | A method of treatment and agents useful for same | |
| AU2004905148 | 2004-09-08 | ||
| US64796805P | 2005-01-27 | 2005-01-27 | |
| US60/647,968 | 2005-01-27 | ||
| PCT/AU2005/001363 WO2006026820A1 (en) | 2004-09-08 | 2005-09-08 | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012030227A Division JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008512394A JP2008512394A (ja) | 2008-04-24 |
| JP2008512394A5 true JP2008512394A5 (enExample) | 2008-10-09 |
| JP5094395B2 JP5094395B2 (ja) | 2012-12-12 |
Family
ID=36036018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530543A Expired - Fee Related JP5094395B2 (ja) | 2004-09-08 | 2005-09-08 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080254023A1 (enExample) |
| EP (1) | EP1793854A4 (enExample) |
| JP (2) | JP5094395B2 (enExample) |
| CA (1) | CA2579352A1 (enExample) |
| NZ (1) | NZ553273A (enExample) |
| WO (1) | WO2006026820A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| WO2006026820A1 (en) * | 2004-09-08 | 2006-03-16 | The University Of Queensland | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
| AU2007272533A1 (en) * | 2006-07-13 | 2008-01-17 | Novartis Ag | Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders |
| US8530181B2 (en) | 2007-11-15 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase |
| US7892769B2 (en) * | 2007-11-30 | 2011-02-22 | Eisai R&D Management Co., Ltd. | Processing of EphA4 polypeptide by γ-secretase activity |
| EP2260864A1 (en) * | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| WO2012081502A1 (ja) | 2010-12-17 | 2012-06-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法 |
| WO2012147798A1 (ja) | 2011-04-25 | 2012-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 |
| US10322161B2 (en) | 2014-07-15 | 2019-06-18 | Sanford Burnham Prebys Medical Discovery Institute | EPHA4 cyclic peptide antagonists for neuroprotection and neural repair |
| RU2651756C1 (ru) * | 2017-05-10 | 2018-04-23 | Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ | Препарат для предотвращения образования глиальных рубцов |
| MA56466A (fr) | 2019-07-01 | 2022-05-11 | Eisai R&D Man Co Ltd | Anticorps anti-epha4 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) * | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| ATE293989T1 (de) * | 1998-11-20 | 2005-05-15 | Genentech Inc | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
| AU2003268345A1 (en) * | 2002-09-24 | 2004-04-19 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| WO2004041197A2 (en) * | 2002-11-01 | 2004-05-21 | Case Western Reserve University | Methods of inhibiting glial scar formation |
| WO2005056766A2 (en) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
| WO2006026820A1 (en) * | 2004-09-08 | 2006-03-16 | The University Of Queensland | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
-
2005
- 2005-09-08 WO PCT/AU2005/001363 patent/WO2006026820A1/en not_active Ceased
- 2005-09-08 JP JP2007530543A patent/JP5094395B2/ja not_active Expired - Fee Related
- 2005-09-08 EP EP05778955A patent/EP1793854A4/en not_active Withdrawn
- 2005-09-08 NZ NZ553273A patent/NZ553273A/en not_active IP Right Cessation
- 2005-09-08 US US11/662,355 patent/US20080254023A1/en not_active Abandoned
- 2005-09-08 CA CA002579352A patent/CA2579352A1/en not_active Abandoned
-
2012
- 2012-02-15 JP JP2012030227A patent/JP2012136529A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Finlin et al. | Mast cells promote seasonal white adipose beiging in humans | |
| Arborelius et al. | Increased responsiveness of presumed 5-HT cells to citalopram in adult rats subjected to prolonged maternal separation relative to brief separation | |
| Hutchinson et al. | Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast) | |
| Daenen et al. | Adaptation and habituation to an open field and responses to various stressful events in animals with neonatal lesions in the amygdala or ventral hippocampus | |
| Knoll et al. | Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats | |
| Million et al. | CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats | |
| Joseph et al. | The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke | |
| JP2008512394A5 (enExample) | ||
| Brait et al. | Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome | |
| Beamer et al. | N w‐Propyl‐l‐arginine (L‐NPA) reduces status epilepticus and early epileptogenic events in a mouse model of epilepsy: behavioural, EEG and immunohistochemical analyses | |
| Klausner et al. | The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat | |
| Covington III et al. | NMDA receptors in the rat VTA: a critical site for social stress to intensify cocaine taking | |
| Ebbinghaus et al. | The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses | |
| LeBlanc et al. | Plasma dopamine and noradrenaline variations in response to stress | |
| Abraham et al. | β1-and β2-adrenoceptor induced synaptic facilitation in rat basolateral amygdala | |
| Matuszewich et al. | Partial antagonism of 8-OH-DPAT'S effects on male rat sexual behavior with a D2, but not a 5-HT1A, antagonist | |
| Yamaoka et al. | Different analgesic effects of adenosine between postoperative and neuropathic pain | |
| Meade et al. | Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy | |
| Chajra et al. | Opioid receptor delta as a global modulator of skin differentiation and barrier function repair | |
| RU2008116567A (ru) | Биомаркеры | |
| Banks et al. | Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy | |
| Maes et al. | Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigs | |
| McGaraughty et al. | Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats | |
| Zhang et al. | Involvement of galanin receptor 2 and CaMKII in galanin-induced antinociception in periaqueductal grey of rats | |
| Loram et al. | Behavioural, histological and cytokine responses during hyperalgesia induced by carrageenan injection in the rat tail |